Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ROPEGINTERFERON ALFA-2B
- Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities
- Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.
- Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis
- A Study Designed to Assess the Efficacy, Safety, and Tolerability of P1101 After the 12 Month Core Treatment Period in Patients With ET.
- A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
- Ropeginterferon Alfa 2b for Early Myelofibrosis
- The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
- Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection
- Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
- Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis
- Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects
- The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV
Clinical trials list
click for details